Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 14Squamous Cell Carcinoma of Head and Neck 12Colorectal Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Breast Neoplasms 10Carcinoma, Renal Cell 7Prostatic Neoplasms 6Head and Neck Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Neoplasms 5Lung Neoplasms 5Biliary Tract Neoplasms 5Small Cell Lung Carcinoma 4Ovarian Neoplasms 4Uterine Cervical Neoplasms 3Urinary Bladder Neoplasms 3Recurrence 3Pancreatic Neoplasms 3Neoplasm Metastasis 3Fallopian Tube Neoplasms 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3Advanced Solid Tumors 3Stomach Neoplasms 2Sarcoma 2Recurrent Squamous Cell Lung Carcinoma 2Liver Neoplasms 2Kidney Neoplasms 2Gallbladder Neoplasms 2Esophageal Squamous Cell Carcinoma 2

Interventions

tremelimumab 1durvalumab 1anlotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignancy × tremelimumab × Clear all
NCT02978482 2021-08-18

A Phase 1/2 Study of Durvalumab(MEDI4736) and Tremelimumab in Chinese Patients With Advanced Malignancies

AstraZeneca

Phase 1 Completed
26 enrolled

Advanced Malignancy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡